Rhythm Theater - Neuromodulation for Heart Failure, a New Therapeutic Frontier. BAROSTIM NEO the World’s First Neuromodulation Therapy for Heart Failure: Clinical Evidence, Patient Selection and Implant Practices

Description

The esteemed group of electrophysiologists and heart failure specialists review autonomic modulation therapies for the treatment of heart failure. The group introduces the BAROSTIM NEO device, the world’s first FDA approved neuromodulation device for the treatment of heart failure. The team discusses BAROSTIM NEO clinical evidence, patient selection, implantation procedure, and the clinical and technological plans for the next generation of BAROSTIM NEO.

Faculty

Chairs:
Thomas F. Deering, MBA, MD, FHRS, CCDS
Bradley Knight, MD, FHRS
Larry Chinitz, MD, FHRS

Speakers:
Michael R. Gold, MD, PhD, FHRS
Luanda Grazette, MD
Marwan Bahu, MD, FHRS
Khaled Awad, MD

For More Information

For more information on BAROSTIM NEO please contact the CVRx team at info@cvrx.com

Summary


Availability:	Retired


Cost:	FREE

Credit Offered:

No Credit Offered

Recommended

HRS 2020 Science- May

Multiple Credits

FREE

HRS 2020 Science Abstract eCatalog

No Credit

FREE

2019 Focused Update of the 2014 Guideline for Management of Patients with Atrial Fibrillation

No Credit

FREE

HRS 2020 Science - Full Program

Multiple Credits

$0.00 - $525.00